Adaptive Biotechnologies combines high-throughput sequencing and bioinformatics to profile T-cell and B-cell receptors in order to drive research in cancer and other immune-mediated diseases. Adaptive’s mission is to translate immunosequencing discoveries into clinical diagnostics and therapeutics to improve patient care.
*Based on Preferred Stock Price, Adaptive Biotechnologies does not have a stock symbol since it is currently private and is yet to have an IPO.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Adaptive Biotechnologies or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.